Logistic model of glucose-regulated C-peptide secretion: Hysteresis pathway disruption in impaired fasting glycemia

American Journal of Physiology - Endocrinology and Metabolism

Volumn 303, Issue 3, 2012, Pages

  Keenan, Daniel M ^a   Basu, Rita ^b   Liu, Yan ^c   Basu, Ananda ^b   Bock, Gerlies ^b   Veldhuis, Johannes D ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MAYO CLINIC   (United States)

^c NexTag Corporation   (United States)

Author keywords

Deconvolution; Insulin; Secretion

Indexed keywords

C PEPTIDE; GLUCOSE; GLUCOSE REGULATED PROTEIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DISORDERS OF CARBOHYDRATE METABOLISM; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHESIS; HYSTERESIS; IN VIVO STUDY; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MEAL; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN SECRETION; STATISTICAL MODEL; WAVELET ANALYSIS; BLOOD; CLINICAL TRIAL; DRUG EFFECT; EATING; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; IMPAIRED GLUCOSE TOLERANCE; METABOLISM; MIDDLE AGED; OSMOLARITY; PHYSIOLOGY; SECRETION (PROCESS); SECRETORY PATHWAY; STATISTICS; TIME;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; EATING; FASTING; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PREDIABETIC STATE; SECRETORY PATHWAY; TIME FACTORS;

EID: 84864504467     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00494.2011     Document Type: Article

References (37)

1. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29: 510-514, 2006.
2. Basu R, Di Camillo B, Toffolo G, Basu A, Shah P, Vella A, Rizza R, Cobelli C. Use of a novel triple-tracer approach to assess postprandial glucose metabolism. Am J Physiol Endocrinol Metab 284: E55-E69, 2003.
3. Bock G, Dalla MC, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55: 3536-3549, 2006.
4. Bock G, Dalla MC, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R. Effects of nonglucose nutrients on insulin secretion and action in people with pre-diabetes. Diabetes 56: 1113-1119, 2007.
5. Bouman PR, Wolters GH, Konijnendijk W. Insulin secretion and cyclic adenosine 3=,5=-monophosphate levels in pancreatic islets of fed and fasted rats. Time course and dose kinetics during glucose stimulation. Diabetes 28: 132-140, 1979.
6. Brandt A, Katschinski M, Arnold R, Polonsky KS, Goke B, Byrne MM. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab 281: E242-E247, 2001.
7. Cerasi E, Fick G, Rudemo M. A mathematical model for the glucose induced insulin release in man. Eur J Clin Invest 4: 267-278, 1974.
8. De Feo P, Perriello G, Torlone E, Ventura MM, Fanelli C, Santeusanio F, Brunetti P, Gerich JE, Bolli GB. Contribution of cortisol to glucose counterregulation in humans. Am J Physiol Endocrinol Metab 257: E35-E42, 1989.
9. Del Prato S, Marchetti P. Beta-and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 36: 775-781, 2004.
10. Filipponi P, Gregorio F, Cristallini S, Ferrandina C, Nicoletti I, Santeusanio F. Selective impairment of pancreatic A cell suppression by glucose during acute alloxan-induced insulinopenia: in vitro study on isolated perfused rat pancreas. Endocrinology 119: 408-415, 1986.
11. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54: 1808-1815, 2005.
12. Grenander U. On the theory of mortality measurement. Skand Aktuarie Tidskrift 1-55, 1956.
13. Grill V, Adamson U, Rundfeldt M, Andersson S, Cerasi E. Glucose memory of pancreatic B and A2 cells: evidence for common timedependent actions of glucose on insulin and glucagon secretion in the perfused rat pancreas. J Clin Invest 64: 700-707, 1979.
14. Gunawardana SC, Rocheleau JV, Head WS, Piston DW. Mechanisms of time-dependent potentiation of insulin release: involvement of nitric oxide synthase. Diabetes 55: 1029-1033, 2006.
15. Hope KM, Tran PO, Zhou H, Oseid E, Leroy E, Robertson RP. Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis. Diabetes 53: 1488-1495, 2004.
16. Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA. Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 41: 548-554, 1998.
17. Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB. Islet beta-cell secretion determines glucagon release from neighbouring alphacells. Nat Cell Biol 5: 330-335, 2003.
18. Israelian Z, Szoke E, Woerle J, Bokhari S, Schorr M, Schwenke DC, Cryer PE, Gerich JE, Meyer C. Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism 55: 593-598, 2006.
19. Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, Reaven GM. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 82: 1834-1838, 1997.
20. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43: 1066-1084, 1994.
21. Keenan DM, Alexander SL, Irvine CHG, Clarke IJ, Canny BJ, Scott CJ, Tilbrook AJ, Turner AI, Veldhuis JD. Reconstruction of in vivo time-evolving neuroendocrine dose-response properties unveils admixed deterministic and stochastic elements. Proc Natl Acad Sci USA 101: 6740-6745, 2004.
22. Kjems LL, Kirby BM, Welsh EM, Veldhuis JD, Straume M, McIntyre SS, Yang D, Lefebvre P, Butler PC. Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50: 2001-2012, 2001.
23. Koeslag JH, Saunders PT, Terblanche E. A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitus-syndrome X complex. J Physiol 549: 333-346, 2003.
24. Kovacevic J, Sweldens W. Wavelet families of increasing order in arbitrary dimensions. IEEE Trans Image Process 9: 480-496, 2000.
25. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329: 1988-1992, 1993.
26. Meier JJ, Kjems LL, Veldhuis JD, Lefebvre P, Butler PC. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 55: 1051-1056, 2006.
27. Nesher R, Cerasi E. Modeling phasic insulin release: immediate and time-dependent effects of glucose. Diabetes 51: S53-S59, 2002.
28. Nomura M, Shichiri M, Kawamori R, Yamasaki Y, Iwama N, Abe H. A mathematical insulin-secretion model and its validation in isolated rat pancreatic islets perifusion. Comput Biomed Res 17: 570-579, 1984.
29. O'Brien PC. The appropriateness of analysis of variance and multiplecomparison procedures. Biometrics 39: 787-794, 1983.
30. Pontiroli AE, Perfetti MG, Andreotti AC, Fattor B, Monti LD, Pozza G. Metabolic effects of graded glucagon infusions in man: inhibition of glucagon, insulin, and somatostatin response to arginine. Metabolism 42: 1242-1248, 1993.
31. Prentice RL. A generalization of the probit and logit methods for dose-response curves. Biometrics 32: 761-768, 1976.
32. Ritzel RA, Veldhuis JD, Butler PC. Glucose stimulates pulsatile insulin secretion from human pancreatic islets by increasing secretory burst mass: dose-response relationships. J Clin Endocrinol Metab 88: 742-747, 2003.
33. Singh V, Grotzinger C, Nowak KW, Zacharias S, Goncz E, Pless G, Sauer IM, Eichhorn I, Pfeiffer-Guglielmi B, Hamprecht B, Wiedenmann B, Plockinger U, Strowski MZ. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition. Endocrinology 148: 3887-3899, 2007.
34. Summers RL, Montani JP, Woodward LH, Coleman TG, Hall JE. Theoretical analysis of the mechanisms of chronic hyperinsulinemia. Comput Biol Med 27: 249-256, 1997.
35. Veldhuis JD, Keenan DM, Pincus SM. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev 29: 823-864, 2008.
36. Williams TF, Exton JH, Park CR, Regen DM. Stereospecific transport of glucose in the perfused rat liver. Am J Physiol 215: 1200-1209, 1968.
37. Yao CY, Gill M, Martens CA, Coy DH, Hsu WH. Somatostatin inhibits insulin release via SSTR2 in hamster clonal beta-cells and pancreatic islets. Regul Pept 129: 79-84, 2005.